Hanyoyin Viscosupplement for Knee Osteoarthritis
Monovisc wani maganin cizon sauro ne kawai wanda ake amfani dashi don magance ciwon gwiwa wanda ke osteoarthritis ya shafa. Yana da allurar rigakafi , ma'anarsa, an haɗa shi cikin haɗin gwiwa. Anika Therapeutics, Inc. ne aka kirkiro Monovisc kuma ya karbi karbar tallar kasuwanci daga FDA ta FDA a ranar 25 ga Fabrairu, 2014. Monovisc yana kasuwanci ne daga DePuy Synthes, Mitek Sports Medicine karkashin yarjejeniyar lasisi tare da Anika.
Hyaluronan (gishiri mai rikitarwa na iyali glycosaminoglycan) a cikin Monovisc babban nauyi ne na kwayoyin, ƙananan tsabta na tsabta na hyaluronan na halitta daga asalin dabba. A hyaluronan an samo shi daga kwayoyin kwayoyin cuta kuma an danganta shi da wani bayani mai mahimmanci. Monovisc ya ba da kwatankwacin kwatankwacin zuwa Orthovisc , wani karamin Anika Therapeutics viscosupplement - amma Orthovisc an gudanar da shi a jerin jerin injections guda uku maimakon guda ɗaya.
Shaidawa
An nuna Monovisc don maganin gwiwa na osteoarthritis a cikin marasa lafiya wadanda suka kasa maganin jiyya, irin su maganin miyagun ƙwayoyi da marasa magani na narcotic (misali, acetaminophen ). Sakamakon farko na ciwon osteoarthritis na gwiwa shine lalacewa tiloti wanda zai haifar da ciwo mai yawa da iyakacin iyakar motsi a cikin haɗin gwiwa. A cikin osteoarthritis, akwai abubuwan haɗari tare da ruwa na synovial . Ruwan haɗin gizon ruwa yana saɗa haɗin gwiwa akai-akai, don barin motsi marar iyaka.
Ƙididdigar abubuwa, irin su Monovisc da wasu waɗanda aka yarda da su, sun dawo da kullun, sunada kaya zuwa haɗin gwiwa.
Sakamakon binciken
Tsaro da kuma tasiri daga bayanan da aka gudanar da binciken, wanda ya shafi 369 masu nazarin binciken gwiwa tare da gwiwar osteoarthritis a tsakiya a 31 a cikin Amurka da Kanada shine tushen dalilin amincewar FDA na Monovisc, a cewar Anika Therapeutics.
An bawa mahalarta Monovisc ba tare da izini ba. An kiyasta su don inganta cigaban haɗin gwiwa ta amfani da WOMAC (yammacin Ontario da McMaster Jami'o'in Osteoarthritis Index), musamman neman wadanda suka kamu da cutar Monovisc wanda suka sami ci gaba mai kyau a gwamin WOMAC idan aka kwatanta da masu kula da marasa lafiya a tsawon makonni 12. Yankin tsaro na bincike ya nuna "rashin ƙananan ƙananan abubuwan da ke faruwa" kuma babu wani mummunar matsalar da ya faru tare da Monovisc.
Wasu Viscosupplements
An amince da karar farko a shekarar 1997. Yanzu akwai wasu nau'o'i 5, wanda mafi yawansu suna buƙatar jerin injections maimakon guda ɗaya.
- Hyalgan
- Synvisc da Synvisc-Ɗaya (daya allura da aka yi daga kaji combs)
- Supartz
- Orthovisc
- Euflexxa
Amfani da Viscosupplementation
A shekara ta 2012, rahoto da aka buga a Annals of Internal Medicine ya tabbatar da cewa viscosuplationation bai dace ba kuma mai haɗari. Rahoton ya bayyana cewa cin zarafi yana haifar da rageccen ciwo yayin da yake iya kara haɗari da ƙananan abubuwan da suka faru. Wannan ƙaddamarwa ta dogara ne akan ƙaddamar da bincike na ƙwararrakin 89 da suka shafi marasa lafiya 12,000 na marasa lafiya na osteoarthritis.
Cibiyar Harkokin Kwararren Orthopedic American ta ce, "Cikakken kwayoyin halitta zai iya taimaka wa mutanen da maganin arthritis bai amsa maganin maganin asali ba.Amma mafi mahimmanci idan arthritis ya kasance a farkon matakan (m zuwa matsakaici). Wasu marasa lafiya suna jin zafi a wurin ginin, kuma wasu lokuta da injections ya haifar da ƙara ƙarawa.Ya ɗauki makonni da dama don lura da wani cigaba bayan viscosuplationation Ba dukkan marasa lafiya zasu sami jin zafi ba Idan injections suna da tasiri za a iya maimaita su bayan lokaci, yawanci watanni 6. An yi amfani da kyakkyawan haɗin gwiwar tsawon lokaci har sai bincike ya ci gaba a wannan yanki. "
> Sources:
> FDA ta amince da Monovisc, Sabon Alurar Gurasar Sabon Alkawari don Jiyya na Wuta saboda Osteoarthritis na Knee. Anika Therapeutics. Fabrairu 25, 2014.
Cikakken Viscosupplementation na Osteoarthritis na Knee: A Review System da Meta-bincike. Agusta 7, 2012. Rutjes et al. Annals na Internal Medicine.
> Magungunan Viscosupplementation na Arthritis. OrthoInfo. AAOS. Afrilu 2013.